Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 3,406

Scientists use light to control the logic networks of a cell (w/video)

Luv this.

Proteins are the workhorse molecules of life. Among their many jobs, they carry oxygen, build tissue, copy DNA for the next generation, and coordinate events within and between cells. Now scientists at the University of North Carolina at Chapel Hill have developed a method to control proteins inside live cells with the flick of a switch, giving researchers an unprecedented tool for pinpointing the causes of disease using the simplest of tools: light.

The work, led by Klaus Hahn and Nikolay Dokholyan and spearheaded by Onur Dagliyan, a graduate student in their labs, builds on the breakthrough technology known as optogenetics. The technique, developed in the early 2000s, allowed scientists, for the first time, to use light to activate and deactivate proteins that could turn brain cells on and off, refining ideas of what individual brain circuits do and how they relate to different aspects of behavior and personality.

Multiplexed optogenetic control, using Photo-inhibitable Vav2 (PA-Vav2) and Photo-inhibitable Rac1 (PI-Rac1) in the same cell.

Tiny 3D printed biobots could dispense drug doses from inside your body

Samuel Sia, a professor of biomedical engineering at New York City’s Columbia University, has developed a 3D printed biobot that can be implanted in the body to release controlled doses of drugs. The amazing device can be controlled from outside the body using only magnets.

For patients who have been diagnosed with cancer, treatment options are often few and far between, and in many serious cases, starting an intense course of chemotherapy becomes a necessity rather than a choice. But despite being a powerful weapon against cancer, chemotherapy takes its toll on the body in a number of ways: chronic pain, nausea, fatigue, hair loss, and the chance of infertility are just some of the adverse effects that chemotherapy can present. Fortunately, scientists are working hard to develop more effective ways of delivering chemotherapy drugs, including a new 3D printing method that involves fabricating squishy, “clockwork” micromachines that deliver precise drug doses from within the body.

‘Out-of-the-Box’ Approaches Can Help Combat Antibiotic Resistance

Is it possible to kill bacteria with bacteria?

This is the unorthodox question posed by a team of researchers funded by the Defense Advanced Research Projects Agency (DARPA)—a research and development organization within the U.S. Department of Defense—that is exploring whether an unusual type of bacteria that eats other bacteria could be a new weapon in the fight against drug-resistant infections.

Known as the Pathogen Predator program, the DARPA initiative (led by Dr. Barry Pallotta) is part of a growing effort to seek new and innovative ways to defeat drug-resistant superbugs, which are rapidly evolving to beat even our most powerful antibiotics.

Synthego bags $41M to grow CRISPR synthetic RNA kit biz

Nice.

Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate. The West Coast startup relied heavily on tech VCs for the cash, but also gained validation from having CRISPR pioneer Jennifer Doudna invest in its business.

Redwood City, CA-based Synthego exited stealth in August, four years after it was set up by two former SpaceX computer engineers. In those early years, which were bankrolled by an $8.3 million investment in 2013, Synthego established an automated manufacturing process for guide RNA products that it thinks sets it apart from larger competitors in terms of cost, turnaround time and editing efficiency.

Sythengo has persuaded some big names it is on to something. 8VC, an infrastructure-focused VC that also invested in uBiome, led the round with support from fellow new backers AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities and ZhenFund. Existing investors including Peter Thiel’s Founders Fund and Menlo Ventures also contributed to the Series B round.

/* */